These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 20145147)

  • 21. TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma.
    Selmi A; de Saint-Jean M; Jallas AC; Garin E; Hogarty MD; Bénard J; Puisieux A; Marabelle A; Valsesia-Wittmann S
    Cancer Lett; 2015 Feb; 357(1):412-418. PubMed ID: 25475555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma.
    Gupta A; Williams BR; Hanash SM; Rawwas J
    Cancer Res; 2006 Aug; 66(16):8100-8. PubMed ID: 16912187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.
    Regan PL; Jacobs J; Wang G; Torres J; Edo R; Friedmann J; Tang XX
    Int J Oncol; 2011 Jan; 38(1):105-12. PubMed ID: 21109931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
    Zhang S; Wei JS; Li SQ; Badgett TC; Song YK; Agarwal S; Coarfa C; Tolman C; Hurd L; Liao H; He J; Wen X; Liu Z; Thiele CJ; Westermann F; Asgharzadeh S; Seeger RC; Maris JM; Guidry Auvil JM; Smith MA; Kolaczyk ED; Shohet J; Khan J
    Cancer Lett; 2016 Feb; 371(2):214-24. PubMed ID: 26683771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.
    Chesler L; Goldenberg DD; Collins R; Grimmer M; Kim GE; Tihan T; Nguyen K; Yakovenko S; Matthay KK; Weiss WA
    Neoplasia; 2008 Nov; 10(11):1268-74. PubMed ID: 18953436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.
    Valentijn LJ; Koster J; Haneveld F; Aissa RA; van Sluis P; Broekmans ME; Molenaar JJ; van Nes J; Versteeg R
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19190-5. PubMed ID: 23091029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. E2F proteins regulate MYCN expression in neuroblastomas.
    Strieder V; Lutz W
    J Biol Chem; 2003 Jan; 278(5):2983-9. PubMed ID: 12438307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High mobility group A1 is a molecular target for MYCN in human neuroblastoma.
    Giannini G; Cerignoli F; Mellone M; Massimi I; Ambrosi C; Rinaldi C; Dominici C; Frati L; Screpanti I; Gulino A
    Cancer Res; 2005 Sep; 65(18):8308-16. PubMed ID: 16166307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncolytic adenovirus-mediated short hairpin RNA targeting MYCN gene induces apoptosis by upregulating RKIP in neuroblastoma.
    Li Y; Zhang H; Zhu X; Feng D; Zhang D; Zhuo B; Zheng J
    Tumour Biol; 2015 Aug; 36(8):6037-43. PubMed ID: 25736927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis.
    Slack A; Lozano G; Shohet JM
    Cancer Lett; 2005 Oct; 228(1-2):21-7. PubMed ID: 15927364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
    Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
    PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
    Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE
    Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting MYCN in neuroblastoma by BET bromodomain inhibition.
    Puissant A; Frumm SM; Alexe G; Bassil CF; Qi J; Chanthery YH; Nekritz EA; Zeid R; Gustafson WC; Greninger P; Garnett MJ; McDermott U; Benes CH; Kung AL; Weiss WA; Bradner JE; Stegmaier K
    Cancer Discov; 2013 Mar; 3(3):308-23. PubMed ID: 23430699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation.
    Murphy DM; Buckley PG; Bryan K; Das S; Alcock L; Foley NH; Prenter S; Bray I; Watters KM; Higgins D; Stallings RL
    PLoS One; 2009 Dec; 4(12):e8154. PubMed ID: 19997598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis.
    Murphy DM; Buckley PG; Bryan K; Watters KM; Koster J; van Sluis P; Molenaar J; Versteeg R; Stallings RL
    Mol Carcinog; 2011 Jun; 50(6):403-11. PubMed ID: 21557326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p73alpha isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expression in neuroblastoma cells.
    Horvilleur E; Bauer M; Goldschneider D; Mergui X; de la Motte A; Bénard J; Douc-Rasy S; Cappellen D
    Nucleic Acids Res; 2008 Aug; 36(13):4222-32. PubMed ID: 18583365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MycN is a transcriptional regulator of livin in neuroblastoma.
    Dasgupta A; Peirce SK; Findley HW
    Oncol Rep; 2009 Oct; 22(4):831-5. PubMed ID: 19724862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase.
    Veas-Perez de Tudela M; Delgado-Esteban M; Cuende J; Bolaños JP; Almeida A
    J Neurochem; 2010 May; 113(4):819-25. PubMed ID: 20180881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma.
    Duffy DJ; Krstic A; Halasz M; Schwarzl T; Fey D; Iljin K; Mehta JP; Killick K; Whilde J; Turriziani B; Haapa-Paananen S; Fey V; Fischer M; Westermann F; Henrich KO; Bannert S; Higgins DG; Kolch W
    Oncotarget; 2015 Dec; 6(41):43182-201. PubMed ID: 26673823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells.
    Molenaar JJ; Ebus ME; Geerts D; Koster J; Lamers F; Valentijn LJ; Westerhout EM; Versteeg R; Caron HN
    Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12968-73. PubMed ID: 19525400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.